SARTORIUS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 290.8 USD | -2.09% |
|
+0.27% | -22.04% |
| 04-30 | SARTORIUS : Target cut by -6.1% |  |
| 04-24 | SARTORIUS VORZUEGE : Gets a Buy rating from Berenberg | ZD |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 3.57B 3.84B 5.26B | Sales 2025 * | 4.02B 4.31B 5.92B | Capitalization | 17.22B 18.49B 25.37B |
|---|---|---|---|---|---|
| Net income 2024 * | 213M 229M 314M | Net income 2025 * | 342M 367M 504M | EV / Sales 2024 * | 5.95 x |
| Net Debt 2024 * | 4.05B 4.35B 5.97B | Net Debt 2025 * | 3.82B 4.1B 5.62B | EV / Sales 2025 * | 5.24 x |
| P/E ratio 2024 * |
73.3
x | P/E ratio 2025 * |
51.1
x | Employees | 14,614 |
| Yield 2024 * |
0.3% | Yield 2025 * |
0.41% | Free-Float | 35.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sartorius AG
More press releases
| 1 day | -2.09% | ||
| 1 week | +0.27% | ||
| Current month | -2.75% | ||
| 1 month | -20.33% | ||
| 3 months | -8.86% | ||
| 6 months | +30.40% | ||
| Current year | -22.04% |
1 week
290.79
311.00
1 month
285.00368.00
Current year
285.00423.70
1 year
223.00423.70
3 years
223.00736.22
5 years
177.90736.22
10 years
74.75736.22
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 99-04-30 | |
| Chief Tech/Sci/R&D Officer | 59 | 94-12-31 | |
Volker Niebel
COO | Chief Operating Officer | 67 | 00-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Ebsworth
BRD | Director/Board Member | 69 | 19-12-31 |
| Director/Board Member | 75 | 11-11-28 | |
| Director/Board Member | 58 | 17-04-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 290.8 | -2.09% | 6 |
| 24-05-07 | 297 | -0.67% | 8 |
| 24-05-06 | 299 | -3.86% | 260 |
| 24-05-03 | 311 | +4.71% | 38 |
| 24-05-02 | 297 | +2.41% | 23 |
Delayed Quote OTC Markets, May 08, 2024 at 01:00 pm
More quotes
Sartorius AG is a Germany-based supplier of pharmaceutical and laboratory equipment. It operates in two segments: bioprocess solutions and lab products and services. The bioprocess solutions segment offers integrated solutions for biopharmaceutical manufacture, such as filters for sterilization of biopharmaceutical media, single-use bags for cell cultivation and storage of biopharmaceuticals, membrane adsorbers for purification in bioprocesses, filter technology for clarification, among others. The lab Products and Services segment provides instruments, consumables, and services for laboratories, including laboratory balances, laboratory water systems for storage of purified water, electronic pipettes, filter systems for sample preparation, and membrane filter systems for sterility testing of parenteral.
Calendar
2024-05-16
- Capital Markets Day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
277
EUR
Average target price
329.2
EUR
Spread / Average Target
+18.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -42.09% | 2.85B | |
| +23.15% | 1.95B | |
| +3.08% | 1.72B | |
| +28.27% | 1.26B | |
| -11.16% | 1.02B | |
| -17.21% | 950M | |
| +0.07% | 777M | |
| -23.17% | 643M | |
| +11.79% | 518M |
- Stock Market
- Equities
- SRT3 Stock
- SUVPF Stock